Used in research and development of targeted cancer therapies, particularly for epithelial-derived tumors such as head and neck squamous cell carcinoma. Binds specifically to the CD44v6 epitope, which is overexpressed in various malignancies but limited in healthy tissues, enabling selective targeting. Investigated for use in antibody-drug conjugates (ADCs), where it delivers cytotoxic agents directly to tumor cells, minimizing damage to normal cells. Also applied in diagnostic imaging to detect CD44v6-positive tumors. Its high specificity makes it a valuable tool in preclinical studies evaluating CD44v6 as a therapeutic target.